Broker Notes: Why analysts name City Chic, Viva Energy and ResMed to buy now?

$City Chic Collective Ltd(CCX.AU)$: UBS maintains a buy rating and A$4.50 target price on City Chic shares.
City Chic's outlook is largely unchanged by plus-size retail rival Torrid's plan to clear inventory through its fiscal 2Q, UBS analyst Shaun Cousins says.

$City Chic Collective Ltd(CCX.AU)$: Macquarie Viva at outperform.
An anticipated sharp jump in refining profits may prompt investors in Viva Energy to push for a bumper 1H payout, Macquarie says.Macquarie raises its 2022 and 2023 EPS forecasts for the company by 21% and 13%, respectively, to reflect higher refining margins.

$ResMed Inc(RMD.AU)$: Goldman Sachs have a buy rating and A$34.40 target price on ResMed shares.
The supply-chain pressures on ResMed exceed those on any other Australian medical device company, but they are solely due the demand stemming from rival Philips's product recall, Goldman Sachs analysts say in a note. ASX-listed ResMed would have no major shortages without the Philips recall and the Goldman Sachs analysts think that breathing-tech market growth will normalize as the supply pressures ease.